Search

The severe coronavirus disease 2019 (COVID-19) is associated with increased levels of blood interleukin (IL)-6. Therefore, it is hypothesized that modulating the levels or effects of IL-6 could diminish airway inflammation and alter the course of COVID-19. We conducted a controlled, randomized, double-blind clinical trial on hospitalized patients with severe COVID-19 in Iran. The patients were randomly distributed by block randomization to take either standard-of-care (SOC) plus 1 or 2 doses of tocilizumab 8 mg/kg or SOC alone. The endpoint was defined by clinical improvement and discharge. We enrolled 40 patients (20 patients in each group) from 10 July to 10 December 2020. After randomization, 1 patient in the SOC arm and 3 patients in the tocilizumab arm refused to participate and were eliminated from the study. The mean age of participants was 59.62±15.80 in the tocilizumab group (8 women and 9 men) and 63.52±12.83 years old in the SOC group (9 women and 10 men) groups. The number of patients who recovered did not differ significantly between the tocilizumab and SOC groups (12 [70.6%][70.6%] vs. 15 [78.9%]), respectively). Hospitalization rates were also similar between the groups (Log-rank test, p=0.615; hazard ratio, 0.83; 95% CI [0.39–1.78]). The results show that tocilizumab could not be a beneficial agent for treating severe cases of COVID-19 patients and would not significantly improve clinical outcomes. [ABSTRACT FROM AUTHOR]

Background: Despite assessing the expression of CD11c gene in macrophages in adipose tissues and suggesting association between the gene expressions and predisposing to obesity, the relationship of the changes in CD11c gene and its variants with obesity has not been exclusively evaluated. The present study aimed to assess the relationship between rs2230424 gene polymorphism leading a single amino acid Arginine 48 to Tryptophan interchange in CD11c gene protein chain and obesity in a sample of Iranian population. Methods: This case-control association study was performed on 247 subjects including obese individuals and a sex- and age-matched healthy non-obese individuals. After DNA extraction, the DNA sequence containing the relevant polymorphic site was amplified by polymerase chain reaction (PCR). Determining different genotypic patterns of the SNP was carried out by restriction fragment length polymorphism (RFLP) analysis. To final draft the suspected genotypes of the SNP, DNA sequencing was performed. Results: The frequency of wild genotype (TT) of Trp48Arg polymorphism of the CD11c gene in obese and non-obese groups was 97.9% and 94.6% and the frequency of heterozygous genotype (TC) was 2.1% and 5.4%, respectively with no significant difference (p = 0.230,). None of the participants had mutant genotypic pattern of the polymorphism. There was no association of the genotypic pattern of Trp48Arg polymorphism with different underlying risk factors as well as mean laboratory parameters. Conclusion: The presence of Trp48Arg polymorphism of the CD11c gene is not associated with increased risk for obesity among Iranian population. [ABSTRACT FROM AUTHOR]

Introduction: Estimating the prevalence of SARSCOV-2 antibody sero positivity among health care workers (HCWs) is crucial. In this study the seroprevalence of antiSARS-COV-2 antibodies among HCWs of five hospitals of Tehran-Iran with high COVID-9 patient’s referrals was assessed. Methods: HCWs from public and private hospitals were included and were asked questions on their demographic characteristics, medical history, hospital role and usage of personal protective equipment (PPE). Seroprevalence was estimated on the basis of ELISA test results (IgG and IgM antibodies in blood samples) and adjusted for test performance. Results: Among the 2065 participants, 88.4% and 11.6% HCWs were recruited from the public and private hospitals, respectively. The overall test-performance adjusted seroprevalence estimate among HCWs was 22.6 (95% CI 20.2-25.1) and it was higher in private hospitals (37.0%; 95% CI 28.6-46.2) than public hospitals (20.7%; 95% CI 18.2-23.3). PPE usage was significantly higher among HCWs of public versus private hospitals (66.5% vs. 20.0%). Test-adjusted seroprevalence estimates were highest among assistant nurses and nurses, and lowest among janitor/superintendent categories. Conclusion: Seroprevalence of SARS-COV-2 among HCWs depends on hospital type, hospital department, and hospital role. The PPE usage was especially suboptimal among HCWs in private hospitals. Continued effort in access to adequate PPE is warranted. [ABSTRACT FROM AUTHOR]